医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Announcement Regarding the News Coverage Concerning an Inquiry on Trades of Acucela Shares

2016年06月22日 AM09:28
このエントリーをはてなブックマークに追加


 

SEATTLE

Acucela Inc. (Tokyo:4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that during the Japan Exchange Group’s (“JPX”) regularly scheduled press event on June 21, 2016 (Japan time), it was reported that Japan Exchange Regulation (a subsidiary of JPX) is conducting an inquiry into trades of Acucela shares.

Acucela will endeavor to cooperate fully with inquiries made by Japan Exchange Regulation.

About Acucela Inc.

Acucela Inc. (http://www.acucela.com/ or http://www.acucela.jp) is a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of people worldwide. The Company’s pipeline includes drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, Stargardt disease and cataracts.

“Acucela” and the Acucela logo are registered trademarks or trademarks of Acucela Inc. in various jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160621006639/en/

CONTACT

Acucela Inc.
Michael Hasegawa, +81-3-5789-5872
pr@acucela.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
  • Nanotronics Health Donates Hundreds of Non-Invasive Ventilators for COVID-19 Relief in India, in Collaboration with Transworld Group
  • ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
  • Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
  • Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases